A Study to Learn About How Loss of Liver Function Affects the Blood Levels of the Study Medicine Called PF-07817883.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

21 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-06-15

Study Completion Date

2024-06-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to learn about the safety of PF-07817883 and how PF-07817883 is processed in the body of adult participants. These participants will have different degrees of loss of liver function. Participants with mild, moderate, severe or no loss of liver function will be enrolled in 4 groups.

This study is seeking participants who:

* are male or female of 18- 75 years of age
* either have different amounts of damage to liver function or for one of the groups, no damage
* willing to follow the requirements of the study including stay at clinic for 6 nights and 7 days

About, 6-8 participants will be enrolled in group 1 (participants without loss of liver function) and group 3 (participants with moderate loss of liver function). In group 4 (participants with severe loss of function), around 4 to 8 participants will be enrolled. Participants in group 2 (mild loss of function) will only be enrolled after review of the data from groups 3 and 4.

If participants consent to participate in the study, it may take up to 4 weeks to complete all the tests to confirm if they are eligible to participate in the study. If they seem to be eligible for the study, participants will be admitted to a clinic research unit (CRU) at least 12 hours before dosing. On Day 1, participants will receive a single dose of study medicine (Day 1). A series of blood samples will be collected before and after dosing. Participants will be discharged from the CRU on Day 6. A follow-up phone call (on CRU visit, if needed), will occur 28-35 days after dosing.

The whole study will last for a minimum of 5 weeks and a maximum of 10 weeks.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Compare How the Study Medicine (PF-07923568) is Processed in Participants With Different Levels of Loss of Liver Function to Healthy Participants.

NCT05857644

Liver Diseases Hepatic Impairment

COMPLETED PHASE1

A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver Function

NCT07269301

Hepatic Impairment Healthy

NOT_YET_RECRUITING PHASE1

A Study to Understand How the Study Medicine (PF-07081532) is Processed in People With Liver Dysfunction

NCT05478603

Hepatic Impairment Healthy Volunteers

COMPLETED PHASE1

2-Week Study In People With Nonalcoholic Fatty Liver Disease

NCT03513588

Non-alcoholic Steatohepatitis Non-alcoholic Fatty Liver Disease

COMPLETED PHASE1

Study in Healthy Adults Evaluating PF-07202954

NCT04857437

Non-Alcoholic Fatty Liver Disease Liver Fibrosis

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1

No hepatic impairment

Group Type EXPERIMENTAL

PF-07817883

Intervention Type DRUG

Experimental

Cohort 2

Mild hepatic impairment

Group Type EXPERIMENTAL

PF-07817883

Intervention Type DRUG

Experimental

Cohort 3

Moderate hepatic impairment

Group Type EXPERIMENTAL

PF-07817883

Intervention Type DRUG

Experimental

Cohort 4

Severe hepatic impairment

Group Type EXPERIMENTAL

PF-07817883

Intervention Type DRUG

Experimental

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PF-07817883

Experimental

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* (HI Cohorts Only): Stable HI that meets criteria for Class A or B of the Child-Pugh classification;
* (all Cohorts): BMI of 17.5 to 38.0 kg/m2

Exclusion Criteria

* Limited predicted life expectancy
* Hepatic dysfunction secondary to acute ongoing hepatocellular process.
* Signs of clinically active Grade 2, 3 or 4 hepatic encephalopathy.
* Severe ascites and/or pleural effusion
* History of kidney, liver, or heart transplantation.
* Persistent severe, uncontrolled hypertension.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes